Haohui Fang
Hefei, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Surgical Outcomes of Perioperative Toripalimab in Stage III Resectable Non-Small Cell Lung Cancer: Post Hoc Analysis of the Neotorch Randomized Clinical Trial.
Journal: JAMA surgery
Published: July 15, 2026
Mefatinib versus gefitinib as a first-line treatment for EGFR-mutated non-small cell lung cancer: a randomized, double-blind, multicenter phase III study.
Journal: Signal transduction and targeted therapy
Published: August 25, 2025
Aumolertinib as adjuvant therapy in resected EGFR-mutated non-small-cell lung cancer (ARTS): a double-blind, multicentre, randomised, controlled, phase 3 trial.
Journal: The Lancet. Oncology
Published: August 01, 2025
Dupilumab Efficacy and Safety in Patients With Persistent Asthma: Asia-Pacific Region.
Journal: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
Published: August 02, 2024
Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non-Small Cell Lung Cancer: The Neotorch Randomized Clinical Trial.
Journal: JAMA
Published: January 16, 2024
Corrigendum: Advanced NSCLC patients with EGFR T790M harbouring TP53 R273C or KRAS G12V cannot benefit from osimertinib based on a clinical multicentre study by tissue and liquid biopsy.
Journal: Frontiers in oncology
Published: June 07, 2023
Efficacy and safety of MIL60 compared with bevacizumab in advanced or recurrent non-squamous non-small cell lung cancer: a phase 3 randomized, double-blind study.
Journal: EClinicalMedicine
Published: June 21, 2021
Advanced NSCLC Patients With EGFR T790M Harboring TP53 R273C or KRAS G12V Cannot Benefit From Osimertinib Based on a Clinical Multicentre Study by Tissue and Liquid Biopsy.
Journal: Frontiers in oncology
Published: October 27, 2020
Showing 1-10 of 10
Last Updated: 09/26/2026